Oncogenic c-Myc has been described to modulate the expression of a subset of microRNAs (miRNAs), which include miR-22; however, the mechanism through which a miRNA controls c-Myc activity remains unclear. Here we report a novel anti-c-Myc function mediated by miR-22. Ectopically expressed miR-22 inhibited cell proliferation and anchorage-independent growth of human cancer cell lines. Microarray screening and western analyses revealed that miR-22 repressed the c-Mycbinding protein MYCBP, a positive regulator of c-Myc. Consistent with this, reporter assays showed that miR-22-mediated MYCBP gene suppression largely depends on the conserved miR-22 target site within the MYCBP 3 0 -untranslational region (3 0 UTR), implying that MYCBP mRNA is a direct miR-22 target. Depletion of MYCBP using small interfering RNA (siRNA) recapitulated the miR-22-induced anti-growth effect on tumor cells, whereas ectopically expressed MYCBP rescued cells from the growth suppression mediated by miR-22. Moreover, repression of MYCBP by miR-22 downregulated a panel of E-box-containing c-Myc target genes. Our results suggest that miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. As c-Myc inhibits the expression of miR-22, we propose a novel positive feedback loop formed by oncogenic c-Myc to accelerate cell proliferation by suppressing miR-22, a potent inhibitor of MYCBP.
Introduction
MicroRNAs (miRNAs), a class of endogenous short (B22 nucleotides) non-coding RNAs, are highly conserved throughout evolution (Bartel, 2004) . In mammals, nascent primary miRNAs are transcribed by RNA polymerase II and sequentially processed by two RNase III enzymes, Drosha and Dicer, to produce mature miRNAs. Then mature miRNAs are loaded into an RNA-induced silencing complex, and associated with 3 0 -untranslational region (3 0 -UTR) of mRNAs to suppress their expression (Bartel, 2004) . The miRNAs as a set of crucial regulatory genes have diverse expression patterns, and regulate a broad spectrum of physiological and pathological processes (Esquela-Kerscher and Slack, 2006) .
Through regulating approximately 15% of all genes, the Myc family of transcription factors (c-Myc, N-Myc and L-Myc) have global effects on cell proliferation and growth as key oncogenic transcription factors (Cole and McMahon, 1999; Nesbit et al., 1999; Meyer and Penn, 2008) . The control of c-Myc expression and function involves several mechanisms, one of which is based on the regulatory network of the c-Myc-binding proteins. The MYCBP (AMY-1) gene encodes a small c-Mycbinding protein of B11 kD, that binds the N-terminal domain of c-Myc through its C-terminal region and stimulates E-box-dependent transcriptional activation of c-Myc to promote tumorigenesis (Taira et al., 1998; Sakamuro and Prendergast, 1999) . Several miRNAs have been found to regulate cell proliferation and anchorage-dependent growth (Esquela-Kerscher and Slack, 2006) , but cross-talk between miRNAs and Myc genes has only started to emerge (Chang et al., 2008; Mestdagh et al., 2009) . In this respect, recent studies have shown that c-Myc acts directly as a regulator of a broad panel of miRNAs including miR-22 (Chang et al., 2008; Mestdagh et al., 2009) , but the effects of miRNAs on c-Myc expression and function are largely unknown.
miR-22 was originally identified from HeLa cells as a 22-nucleotide non-coding RNA, and was subsequently shown to be ubiquitously expressed in various tissues (Lagos-Quintana et al., 2001 Neely et al., 2006) . The human miR-22 gene is located in a minimal loss of heterozygosity region between markers D17S1866 and D17S1574 on chromosome 17 (17p13.3) (close to TP53) in cancer cells (Supplementary Figure 1a) , and the mouse miR-22 gene is also mapped to a cancerassociated genomic region (Suzuki et al., 2002; Calin et al., 2004) . The human miR-22 gene overlaps the exon 2 region of the spliced non-coding C17orf91 transcript, and primary miR-22 is processed from a capped, polyadenylated transcript (Cai et al., 2004; Rodriguez et al., 2004) (Supplementary Figure 1b) . In addition, the miRNA editing event by adenosine-deaminases acting on RNA, was first described for the precursor miR-22 (Luciano et al., 2004) (Supplementary Figure 1c) .
Phylogenetic analysis showed that miR-22 is highly conserved evolutionarily among vertebrates, and this serves as an indicator for its critical biological role in vertebrates ( Supplementary Figures 1d and e) . Systematic genomic discovery of regulatory motifs in the 3 0 -UTR of several mammals revealed that miR-22 ranks top among all the miRNAs in terms of having the most potential target genes (Xie et al., 2005) . Two recent studies showed that for a subset of human tumors, impairment of HIVtransactivating response RNA-binding protein or c-Myc expression is correlated with defects in the expression of miRNAs including miR-22 (Chang et al., 2008; Melo et al., 2009) , and this suggests a potential involvement of miR-22 in the suppression of tumorigenesis. Therefore, we decided to examine the role of miR-22 in a tumor context.
Results and discussion
miR-22 suppresses proliferation and anchorageindependent growth of human cancer cell lines We first determined the effect of miR-22 on human tumor cell proliferation and colony formation. A negative control RNA duplex with irrelevant sequences (control RNA, Supplementary Figure 2 ) was used to eliminate potential non-sequence-specific effects (Su et al., 2009) . For the cell proliferation assay, MCF-7 human breast cancer cells were transfected with miR-22 duplex (miR-22, Supplementary Figure 2) . Compared with control RNA transfection, our results showed that miR-22 transfection induced a dramatic increase in mature miR-22 in cells (Figure 1a) . It was interesting to find that cells with ectopically expressed miR-22 proliferated markedly more slowly than cells treated with control RNA (Figure 1b) . Subsequently, the soft agar colony assay was used to assess the capacity of miR-22 in mediating anchorageindependent cell growth, and it was shown that that overexpression of miR-22 led to decreased cell numbers and smaller cell colonies than control treatments ( Figure 1c ). The levels of control RNA expression after colony formation were confirmed by quantitative RT-PCR (Supplementary Figure 3a) .
We then used MDA-MB-231 cells, a cell line that expresses miR-22 endogenously at higher levels than MCF-7 cells, to evaluate the effects of anti-sense-based miR-22 knockdown (Figure 1d ). We found that the inhibitor of miR-22 indeed reduced the endogenous miR-22 levels ( Figure 1e ) and promoted cell growth in MDA-MB-231 cells (Figures 1f and g ). These results lend support to the hypothesis that miR-22 is a potent inhibitor of growth in human cancer cells.
Identification of c-Myc-binding protein MYCBP as a target of miR-22
To elucidate the mechanism of tumor suppression by miR-22, an expression array analysis (Gene Expression Omnibus database, accession number GSE17508) was performed on MCF-7 cells transfected with either miR-22 or control RNA using Human Genome U133 plus 2.0 Array from Affymetrix (Affymetrix, Santa Clara, CA, USA). Differentially expressed genes were identified using the two-class unpaired method in Significance Analysis of Microarrays (version 2.23) and filtered at a false discovery rate of p0.05 (Tusher et al., 2001) , and changes in the expression levels of all probes were summarized in Supplementary Table 1. A previous landmark study set 1.4-fold as the cutoff for successful miRNA analysis (Krutzfeldt et al., 2005) . Hence, mRNAs for which expression was downregulated more than 1.4-fold in miR-22-overexpressing MCF-7 cells relative to cells transfected with control RNA were selected and classified using the gene ontology categories (Supplementary Table  2a ). Gene ontology annotations performed using Molecular Annotation System (MAS) 2.0 software revealed that the predominantly affected genes were enriched in the top-ranking category of 'protein binding' ( Table 1) .
The TargetScan program (version 5.1) (Lewis et al., 2003) for prediction of miRNA targets was used to search for potential direct target genes of miR-22 from all 42 genes of the gene ontology 'protein binding' group. Among the 19 genes that contain at least one predicted binding site in their 3 0 -UTR for miR-22, each of the genes LRRC1, DPM2, NPNT, HNRNPA3 and MYCBP contains at least one putative target site that is conserved across mammalian species (Supplementary Table 2b ). As miR-22 has a tumor-suppressive activity on tumor cell lines, and among these genes, only MYCBP was previously reported to have functions related to tumorigenesis (Taira et al., 1998; Sakamuro and Prendergast, 1999) , we chose MYCBP to verify whether it is a target of miR-22 for mediating the inhibition of proliferation and growth of tumor cell lines. MYCBP is known to contribute to E-box-dependent transcriptional activation of a panel of genes by oncogenic transcription factor cMyc (Sakamuro and Prendergast, 1999) , and thus might link miR-22 to its anti-growth action. MYCBP mRNA levels were monitored in cells overexpressing miR-22 in comparison with cells treated with control RNA. MYCBP mRNA was substantially reduced by miR-22, which was well in line with the approximately twofold decrease observed in the Affymetrix microarray assay (Affymetrix) (Figure 2a ; Supplementary Figure 3b ). We then measured the protein levels of MYCBP, and found that they were indeed lower in miR-22-overexpressing MCF-7 cells than in control cells in a manner that was similar to MYCBP expression changes induced by specific small interfering RNA ( TargetScan, we predicted that MYCBP has an extremely conserved miR-22 target site (positions 38-412 nt ) within its 1704 nt 3 0 -UTR region ( Figure 3a ). The mFold-predicted DG of interaction between miR-22 and the MYCBP target site indicated that miR-22 would bind to this target with high affinity (Figure 3b ). To test whether this site does serve as a true miR-22 target site for mediating MYCBP expression, we constructed a reporter plasmid with the whole B1.7 kb MYCBP 3 0 -UTR (wild-type) or a version with the miR-22 target site mutated (mutant) (Figure 3c ). Treatment of HEK293T or MCF-7 cells with miR-22 had a potent inhibitory effect on the luciferase activity (Figure 3d ). The mRNA levels from the wild-type reporter plasmid were markedly reduced as well but this was not observed when the mutant reporter plasmid was used (Figure 3e ). We further measured the expression of the two reporters in MDA-MB-231 cells while manipulating endogenous miR-22 levels with an anti-sense antagonist. Antagonism of endogenous miR-22 significantly increased the relative luciferase activity and mRNA levels of the wild-type reporter, and this enhanced activity was completely absent when the mutant vector was used (Figures 3f and g ), suggesting that this conserved target site does constitute an essential element for MYCBP regulation by miR-22. Taken together, these functional studies suggested that miR-22 directly targets the MYCBP 3 0 -UTR to achieve its silencing effect on MYCBP expression.
MYCBP is potentially involved in miR-22-regulated human cancer cell growth To investigate whether MYCBP is involved in the regulation of human cancer cell growth by miR-22, we designed MYCBP-specific siRNAs and constructed a MYCBP-expressing vector containing the entire MYCBP coding sequence without the 3 0 -UTR of MYCBP mRNA. This construct produced MYCBP protein while evading 3 0 -UTR-mediated repressions by miR-22 (Figure 4a ). First, we established that the reduction of MYCBP expression by siRNA mimicked the anti-growth effect of miR-22. The results showed that MYCBP knockdown had inhibitory effects on the proliferation and colony formation of MCF-7 cells, on a scale similar to that found in this cell line with miR-22 overexpression. Moreover, overexpression of MYCBP partially relieved the inhibitory effect of miR-22 on the proliferation and colony formation of MCF-7 cells (Figures 4b and c ; Supplementary Figure 3d and e). These results provide evidence that the tumor suppressive activities of miR-22 are mediated, at least in part, by directly limiting MYCBP expression.
miR-22 might constitute a feedback loop with c-Myc and MYCBP
Previous studies have shown that MYCBP is engaged in the activation of E-box-dependent transcription by c-Myc to promote tumor cell growth (Taira et al., 1998; Sakamuro and Prendergast, 1999) . Our study pinpointed MYCBP as a direct target of miR-22, thus . At 48 h post-transfection, total RNAs were isolated using TRI Reagent (Sigma, St Louis, MO, USA) and converted into cDNA using ImPro-II Reverse Transcriptase (Promega, Madison, WI, USA) for MYCBP mRNA quantification normalized against glyceraldehyde 3-phosphate dehydrogenase by qRT-PCR. Detection primers for MYCBP and GAPDH are included in Supplementary Table 3 . Data are presented as mean ± s.d. from at least three independent experiments (a). Total cellular proteins were prepared and subjected to immunoblot assay for MYCBP protein measurement relative to b-actin using antibodies for human MYCBP (Abcam, Cambridge, UK), b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and an ECL kit (Santa Cruz Biotechnology). The intensity of protein bands was quantified using Image J software (National Institutes of Health, Bethesda, MD, USA) (b, c) miR-22 knockdown increases MYCBP protein yields. Transfection with 200 nM anti-miR-22 or control anti-miR in MDA-MB-231 cells was carried out for the immunoblot assay as in (b). The normalized MYCBP expression for control-RNA-treated cells was set at 1. ***Po0.001. miR-22 targeting MYCBP in cancer J Xiong et al making miR-22 a likely indirect regulator of E-boxdependent transcription. To test this assertion, we selected several well identified E-box-dependent target genes, which include cyclin D2, cyclin-dependent kinase 4, ornithine decarboxylase, lactate dehydrogenase-A, carbamoyl phosphate synthase-aspartate transcarbamylasedihydroorotase, nucleolin and eukaryotic translation initiation factor 2A. (Patel et al., 2004; Meyer and Penn, 2008) . These genes all lack predicted target sites of miR-22 in their 3 0 -UTR as analyzed by TargetScan, thus ruling out a direct interaction between miR-22 and these genes. Using an effective siRNA against MYCBP as a positive 0 -UTR-containing reporter constructs. pGL3m was reconstructed from a Firefly luciferase expressing vector pGL3-control (Promega) by inserting a multiple cloning sequence immediately downstream from the Xba I site, including EcoR V, Apa I, Sac II, Nde I, Pst I, EcoR I and Nru I sites. The insertion site was immediately downstream from the stop codon of the Firefly luciferase reporter gene. A B1.7 kb fragment encoding the full-length 3 0 -UTR of MYCBP mRNA (Genbank accession no. NM_012333) was cloned between the Xba I and Sac II sites in pGL3m, in which the putative complementary site for the miR-22 seed region was either left intact (pGL3m-MYCBP-3 0 -UTR-WT, referred to as wild-type) or mutated ( pGL3m-MYCBP-3 0 -UTR-Mut, referred to as Mut). Subcloning primers for MYCBP 3 0 -UTR are included in Supplementary Table 3 and all the construct products were validated by sequencing. (d, e) Luciferase reporter assay in HEK293T and MCF-7 cells, with cotransfection of wild-type or mutant reporter, and control RNA or miR-22 as designated. At 48 h post-transfection, luciferase activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega) and a Synergy HT microplate fluorescence reader (Bio-Tek Instruments, Winooski, VT, USA), and luciferase mRNA levels were measured by qRT-PCR. The pRL-TK vector constitutively expressing Renilla luciferase was cotransfected as an internal control to minimize experimental variability caused by differences in cell viability or transfection efficiency. (f, g) Luciferase reporter assay in MDA-MB-231 cells treated with control anti-miR or anti-miR-22, was carried out as in (d, e). Transfections were done in duplicate and data are presented as mean±s.d. from at least three independent experiments. **Po0.01; ***Po0.001.
miR-22 targeting MYCBP in cancer
J Xiong et al control, we found that miR-22 had a significant inhibitory effect on the expression of E-box-containing genes in a way similar to siRNA-mediated knockdown of MYCBP. In addition, this effect was significantly rescued by reintroduction of an MYCBP expression vector, free of miR-22 repression (Figures 5a and b; Supplementary  Figure 3f ).
One further question we addressed was whether miR-22 interacts with c-Myc directly in the downregulation of E-box-containing genes. In silico analysis using TargetScan showed no conserved binding sites for miRNAs within the short c-Myc 3 0 -UTR (467 nt), and more specifically, no potential binding sites for miR-22 were found through the whole length of c-Myc mRNA These results ruled out the possibility of a direct interaction between miR-22 and c-Myc, thus strengthening the hypothesis that miR-22 regulates E-boxcontaining c-Myc target genes through direct downregulation of MYCBP. It is not fully established how MYCBP regulates these E-box-containing genes because of growing evidence about the function of MYCBP (Furusawa et al., 2001 Yukitake et al., 2002; Ishizaki et al., 2006) , but there is evidence suggesting that MYCBP acts, at least in part, through modulating the transactivation activity of c-Myc to enhance the transcription of these genes (Taira et al., 1998; Sakamuro and Prendergast, 1999) . Recent studies showed that some c-Myc-mediated miRNAs were implicated in tumorigenesis, embryonic stem cell differentiation and glutamine metabolism (He et al., 2005; O'Donnell et al., 2005; Dews et al., 2006; Chang et al., 2008; Sander et al., 2008; Gao et al., 2009; Lin et al., 2009; Mestdagh et al., 2009) . However, only two miRNAs were found to modulate c-Myc, whereas c-Myc is not their significant targets (Sampson et al., 2007; Lal et al., 2009) . Our results suggest a novel schematic model for miR-22 suppression of c-Mycmediated transactivation through targeting MYCBP in a feedback manner (Figure 5e ). Comparative genomics assay showed that all c-Myc genes from higher eukaryotic species have evolved to bear only an extremely short 3 0 -UTR, which could presumably serve as a perfect strategy for a gene to avoid direct posttranscriptional regulation by the miRNA repertoire. In contrast, MYCBP retains a relatively lengthy 3 0 -UTR (1704 nt) that could accommodate more miRNA manipulation (Figure 5f ). These findings prompted the hypothesis that the indirect regulation of c-Myc activity by miR-22 through modulating the expression of its cofactor MYCBP represents a general model for miRNAmediated regulation of c-Myc.
In summary, we report that miR-22 functions as a tumor suppressor to strongly inhibit the growth of human cancer cell lines, at least in part, by directly targeting the 3 0 -UTR of MYCBP mRNA. This discovery allowed us to propose a loop-like regulation scheme that includes miR-22, c-Myc and MYCBP for the control of proliferation and anchorage-independent growth of cancer cell lines. This has expanded our knowledge of the complexity of miRNA-mediated regulation and made it appealing to explore whether miRNAs fill many of the missing links within current gene regulatory networks. These results improve our understanding of the functional role of miR-22 and suggest that it is worthwhile to explore whether miR-22 can serve as a therapeutic agent for the treatment of human malignancies.
